CD4 and neoplasm: We believe that understanding the mechanisms underlying the MHC class II semiallogeneic DC vaccine, including identifying related stimulator or suppressor CD4+ T cells or altering the tumor microenvironment, will pave the way for promising new DC-based cancer immunotherapies beyond what could be accomplished by the cell fusion approach.